AbbVie Inc.

ABBV

$256.15

+1.09%

N/A+$2.77

Healthcare

Drug Manufacturers - General

NYSE

활발히 거래 중

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio ...

ABBV 최근 뉴스

Quartr2026. 7. 14.Somewhat-Bullish (0.319)

Alector (ALEC) Goldman Sachs 45th Annual Global Healthcare Conference Summary

This article summarizes Alector's presentation at the Goldman Sachs 45th Annual Global Healthcare Conference, highlighting its strategic focus on eradicating neurodegenerative diseases by leveraging human genetics, immunology, and neuroscience. The company's clinical pipeline includes late-stage programs for Alzheimer's and frontotemporal dementia, with key upcoming milestones such as data readouts for AL002 and latozinemab expected by year-end and 2025, respectively. Alector aims to file at least one new IND annually and is integrating blood-brain barrier technology to enhance drug delivery.

ABC11 News2026. 7. 13.Bullish (0.433)

AbbVie pharmaceutical project moves forward in Durham: 'Huge deal'

Durham County leaders are considering a $15 million incentive package for AbbVie, a major pharmaceutical company planning a $1.4 billion investment in a new Durham campus. This project highlights the region's growing pharmaceutical industry and the role of local institutions like Durham Technical Community College in providing a skilled workforce. Construction is expected to finish by late 2028, with county officials emphasizing the economic benefits for the area.

Stock Titan2026. 7. 13.Bullish (0.380)

Apogee Therapeutics (NASDAQ: APGE) backs AbbVie’s $135.11‑per‑share all‑cash deal

Apogee Therapeutics (NASDAQ: APGE) has agreed to be acquired by AbbVie through a merger, where Apogee shareholders will receive $135.11 in cash per share. This all-cash deal represents a 53% premium to Apogee’s closing price on June 17, 2026, and a 63% premium to its 30-day volume-weighted average price. The acquisition has been unanimously recommended by Apogee's board of directors, and shareholders are scheduled to vote on the merger agreement on August 11, 2026.

GuruFocus2026. 7. 13.Neutral (0.031)

ABBV Maintained by UBS -- Price Target Raised to $260

UBS analyst Michael Yee maintained a 'Neutral' rating for AbbVie (ABBV) while increasing the price target from $230.00 to $260.00. Despite the positive outlook reflected by the raised price target, GuruFocus indicates ABBV is currently overvalued by 16.4%, with a GF Value™ of $212.31 compared to its current price of $247.19. The company has a strong GF Score™ of 81/100, driven by high profitability and growth, but a weaker financial strength rating, suggesting investors should be cautious.

marketscreener.com2026. 7. 13.Bullish (0.383)

BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating

BMO Capital has increased its price target for AbbVie (ABBV) from $258 to $300, while maintaining an "Outperform" rating on the stock. This adjustment reflects BMO Capital's continued positive outlook on the biopharmaceutical company. The report also notes other recent analyst actions, including UBS adjusting its target to $260 and RBC raising its target to $280, both maintaining their respective ratings.

AbbVie Inc.

ABBV 최근 뉴스

Alector (ALEC) Goldman Sachs 45th Annual Global Healthcare Conference Summary

AbbVie pharmaceutical project moves forward in Durham: 'Huge deal'

Apogee Therapeutics (NASDAQ: APGE) backs AbbVie’s $135.11‑per‑share all‑cash deal

ABBV Maintained by UBS -- Price Target Raised to $260

BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating

Alector (ALEC) Goldman Sachs 45th Annual Global Healthcare Conference Summary

AbbVie pharmaceutical project moves forward in Durham: 'Huge deal'

Apogee Therapeutics (NASDAQ: APGE) backs AbbVie’s $135.11‑per‑share all‑cash deal

ABBV Maintained by UBS -- Price Target Raised to $260

BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating

The Real Case for Buying Johnson & Johnson (JNJ) Before July 15

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

AbbVie stock holds steady after a new U.S. market backdrop

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

Which is the Better Choice for Healthcare Investors? IYH or BBH?

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Eli Lilly & Co (LLY)

BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $276

West Pharmaceutical Services (WST) Sells SmartDose Rights, Is The Stock Fully Priced?

West Pharmaceutical Services (WST) Sells SmartDose Rights, Is The Stock Fully Priced?

Apogee Therapeutics CEO Michael Henderson sells $2.67m in stock

Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner

West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business

West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business

ABBV Maintained by B of A Securities -- Price Target Raised to $276

AbbVie Inc. Stock 12‑Month Price Target Raised to $263.72, Implies 6% Upside

Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 7.27% on Jul 10: What Signal Does It Send?

Does EyePoint’s (EYPT) Broad Russell Index Debut Quietly Recast Its DURAVYU‑Centric Investor Base?

ABBV Maintains Overweight Rating -- Price Target Raised to $295

AbbVie to buy Apogee Therapeutics for $10.9 billion in cash

RBC Raises Price Target on AbbVie to $280 From $260, Keeps Outperform Rating

BofA Securities Adjusts AbbVie Price Target to $276 From $234

AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note

Precigen (PGEN) In Focus As Russell Removal Tests Its Undervalued Narrative

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?

AbbVie Inc. stock outperforms competitors despite losses on the day

GSK ends brain drug alliance with Alector

WST Completes SmartDose Sale to AbbVie to Focus on Core Growth

WST Completes SmartDose Sale to AbbVie to Focus on Core Growth

GSK ends Alector alliance as both lead assets fail

Guggenheim Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $261

AbbVie stock trades steadily as investors weigh immunology and oncology pipeline

Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress

Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress

Moderna (MRNA) Settles Vaccine Patent Case With $950 Million Upfront Payment

AbbVie (ABBV) Wins EU Approval For Tepkinly, Is The Stock Fully Valued?

AbbVie accused of hiding painful lump risk from Juvederm patients in new lawsuit

Wellington-affiliates report 564,326 APGE shares (APGE) ownership update

Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?

AbbVie Stock Traded Its Old Story for New Growth. Here Is The Price.

AbCellera Biologics (ABCL) Stifel 2025 Healthcare Conference Summary

Abivax: Wall Street Catches Up to the Data